In the phase 1b JAVELIN study, patients with tumors with higher expression levels of PD-L1 were more likely to exhibit tumor response during treatment with avelumab 23 in both the second-line and maintenance settings than those with lower tumor PD-L1 expression. Here, CD274 is linked to neoplasm.